First Study of Oral...
 
Notifications
Clear all

First Study of Oral Artenimol-R in Advanced Cervical Cancer: Clinical Benefit, Tolerability and Tumor Markers

1 Posts
1 Users
2 Likes
328 Views
Daniel
(@daniel)
Admin
Joined: 7 years ago
Posts: 1156
Topic starter  

Background/Aim: Artenimol-R is cytotoxic in transformed cervical cells and safety in humans is yet to be established. The present study investigates the clinical benefits, safety and the tumor marker effect of orally administered Artenimol-R in patients with advanced cervix carcinoma. Patients and Methods: Ten patients were treated with Artenimol-R for 28 days. Clinical symptoms, vaginal discharge and pain were followed-up. Adverse events were recorded. Biopsy samples were analyzed by immunohistochemistry for the expression of relevant tumor markers. Results: Artenimol-R treatment induced clinical remission with a median time for the disappearance of the symptoms being 7 days. No adverse events of grade 3 or 4 occurred. The expression of p53, Epidermal growth factor receptor (EGFR), and antigen Ki-67 as a cellular marker of proliferation, as well as the number of blood vessels stained by the CD31 antibody decreased, whereas the expression of transferrin receptor protein 1 (CD71) increased. Conclusion: The current pilot study provides evidence on the improvement of the clinical symptoms and the good tolerability of Artenimol-R in patients with advanced carcinoma of the cervix uteri. A survival trial with Artenimol-R in advanced patients is warranted.

The 28-day artenimol-R treatment period induced clinical remission in all patients treated. The median time for the disappearance of vaginal discharge and pain was 7 days. The effect on symptoms of the disease was prolonged after the initial treatment period.

https://ar.iiarjournals.org/content/31/12/4417


   
Manuone and Manuone reacted
Quote
Share: